[Skip to Navigation]
Views 489
Citations 0
Comment & Response
November 4, 2020

Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy

Author Affiliations
  • 1University of Pittsburgh, Pittsburgh, Pennsylvania
  • 2Department of Dermatology, University of Minnesota, Minneapolis
JAMA Dermatol. 2020;156(12):1380-1381. doi:10.1001/jamadermatol.2020.4380

To the Editor We read with interest the recent phase 3 clinical trial data1 and Barbieri’s accompanying Editorial2 on the use of clascoterone, a novel topical antiandrogen, in treating moderate to severe facial acne. In the Editorial,2 Barbieri highlights the need to identify specific subgroups or acne phenotypes for which topical antiandrogens may be most effective. Of critical consideration, and not discussed in either the clinical trial1 or Editorial,2 topical antiandrogens may be particularly helpful for managing acne in individuals receiving masculinizing hormone therapy (MHT).

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words